US 2025/0223293 A1Published application

Trem2 modulators

AssigneeMuna Therapeutics ApS

InventorsJakob Busch-Petersen, Gavin Whitlock

Life of this patent

Estimating the term…

Abstract

The present invention relates to compounds useful for modulating Triggering Receptor Expressed on Myeloid Cells-2 (“TREM2”). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TREM2, such as neurodegenerative diseases, and to pharmaceutical compositions comprising the compounds.

Claims22

Dependent claims

1-154. (canceled)

Dependencies are inferred from the claim text.

Facts

Application: 19/009,637Filed 3 Jan 2025
Priority: EP 24150291.34 Jan 2024
Published: 10 Jul 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems

Family

US 12,459,952 B2Related patent
US 2025/0223293 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results